NCT00439270View on ClinicalTrials.gov

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

February 29, 2012

Study Completion Date

January 31, 2013

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

Dasatinib

Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression

DRUG

Docetaxel

Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.

Trial Locations (5)

10960

Hematology-Oncology Associates Of Rockland, Nyack

27710

Duke University, Durham

60637

University of Chicago, Chicago

62703

Springfield Clinic, Springfield

77030-4009

The University Of Texas Md Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY